Drug intelligence / Profile preview

AbelaDrug200

Development stage: Phase 2
Lead developer: Abela Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous

Overview

AbelaDrug200 is a small molecule drug initially developed by Abela Pharmaceuticals. It is being investigated for the treatment of nervous system diseases, with a primary focus on severe head trauma and brain injuries. The drug has undergone Phase 1/2 clinical trials to assess its safety and preliminary efficacy in patients with closed, severe head injury (Glasgow Coma Scale 4-8). The hypothesized mechanism is to lower intracranial pressure, reduce mortality, and improve neurological outcomes following traumatic brain injury. As of the latest updates, its highest global R&D status remains pending[1][2].

Beyond the preview

Go deeper on AbelaDrug200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AbelaDrug200.

Explore the full profile